JPY 3,790.00
+5.28%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenJPY 3,790.00
From 52W high−14.06%
Volume153800.00
Market capJPY 186.57B
P/E (TTM)22.6x
P/S (TTM)0.7x
Div yield2.11%
Key dataSep 18, 2026
Open
JPY 3,790.00
From 52W high
−14.06%
Volume
153800.00
Market cap
JPY 186.57B
ValuationView details →
P/E (Fwd)
11.4x
EV/EBITDA
9.3x
P/E (TTM)
22.6x
RSI (14)
49.5
MomentumView details →
1D Return
+5.28%
YTD Return
+1.92%
Similar companies
Latest newsMore news →
Sawai Pharmaceutical and Towa Pharmaceutical, the two major generic drugmakers under Sawai Group Holdings, are increasing production and supply of the anti-influenza generic oseltamivir in response to an unusually early flu season.3d agoTowa Pharmaceutical announced it received additional regulatory approval for its lenalidomide capsules 2.5mg/5mg 'TOWA', expanding the indications to include relapsed or refractory follicular lymphoma and marginal zone lymphoma, along with corresponding dosage and administration.25d agoTowa Pharmaceutical announced on August 17 that it obtained manufacturing and marketing approval for 18 generic drug products across 7 ingredients, including first-time approvals for 4 ingredients such as guanfacine extended-release tablets for ADHD and linagliptin tablets for type 2 diabetes.34d ago